Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling

Siwei Wei, Yuliana Suryani, G. A. Nagana Gowda, Nicholas Skill, Mary Maluccio, Daniel Raftery

Research output: Contribution to journalArticle

15 Scopus citations


Hepatocellular carcinoma (HCC) accounts for most liver cancer cases worldwide. Contraction of the hepatitis C virus (HCV) is considered a major risk factor for liver cancer. In order to identify the risk of cancer, metabolic profiling of serum samples from patients with HCC (n=40) and HCV (n=22) was performed by 1H nuclear magnetic resonance spectroscopy. Multivariate statistical analysis showed a distinct separation of the two patient cohorts, indicating a distinct metabolic difference between HCC and HCV patient groups based on signals from lipids and other individual metabolites. Univariate analysis showed that three metabolites (choline, valine and creatinine) were significantly altered in HCC. A PLS-DA model based on these three metabolites showed a sensitivity of 80%, specificity of 71% and an area under the receiver operating curve of 0.83, outperforming the clinical marker alpha-fetoprotein (AFP). The robustness of the model was tested using Monte-Carlo cross validation (MCCV). This study showed that metabolite profiling could provide an alternative approach for HCC screening in HCV patients, many of whom have high risk for developing liver cancer.

Original languageEnglish (US)
Pages (from-to)701-716
Number of pages16
Issue number4
StatePublished - Oct 10 2012


  • Hepatocellular carcinoma
  • Heptatitis C
  • Metabolomics
  • NMR

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology

Fingerprint Dive into the research topics of 'Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling'. Together they form a unique fingerprint.

  • Cite this

    Wei, S., Suryani, Y., Nagana Gowda, G. A., Skill, N., Maluccio, M., & Raftery, D. (2012). Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling. Metabolites, 2(4), 701-716. https://doi.org/10.3390/metabo2040701